Retatrutide: The Triple Agonist That Lost 71 lbs in Trials

Retatrutide is the drug that may redefine how the medical world thinks about pharmacological weight loss. In one Phase 3 clinical trial, participants lost an average of 71.2 lbs (32.3 kg) over 68 weeks. That is the highest average weight loss ever recorded for any drug in any clinical trial in history.

It is not yet available. But understanding what it is, how it works, and what the data shows matters — because retatrutide will almost certainly change the treatment landscape when it arrives.

What is retatrutide?

Retatrutide (development code LY3437943) is a once-weekly subcutaneous injection developed by Eli Lilly. It is sometimes called the "triple agonist" or "triple G" because it simultaneously activates three distinct hormone receptors:

• GIP receptor (glucose-dependent insulinotropic polypeptide): stimulates insulin release, regulates fat metabolism and fat cell function
• GLP-1 receptor (glucagon-like peptide-1): suppresses appetite powerfully, slows gastric emptying, stimulates glucose-dependent insulin release
• Glucagon receptor: increases energy expenditure, promotes fat breakdown in the liver, reduces liver fat

Every approved GLP-1 medication activates a subset of these receptors:

• Ozempic/Wegovy (semaglutide): GLP-1 only
• Mounjaro/Zepbound (tirzepatide): GLP-1 + GIP
• Retatrutide: GLP-1 + GIP + glucagon

The addition of the glucagon receptor component is the key differentiator.

The glucagon paradox: why adding a hunger-stimulating hormone helps

Glucagon is known primarily as a hormone that raises blood sugar — the opposite of insulin. It also stimulates appetite. So why does activating glucagon receptors help with weight loss rather than hinder it?

The answer is mechanism and context.

In isolation and at high levels, glucagon does stimulate appetite and raise blood glucose. But when activated alongside GLP-1 and GIP — which strongly suppress appetite and lower blood sugar — the glucagon component contributes its unique metabolic benefits without its appetite-stimulating downside:

Increased energy expenditure: Glucagon receptor activation raises basal metabolic rate. The body burns more calories at rest. This is an additional weight loss lever that GLP-1 and GIP alone do not provide.

Enhanced fat breakdown: Glucagon promotes lipolysis (breaking down stored fat) and specifically targets liver fat (hepatic steatosis). For patients with fatty liver disease — common with obesity — this is an additional benefit.

Thermogenic effect: Glucagon activates brown adipose tissue (brown fat), which burns energy as heat rather than storing it.

When these three mechanisms work together — strong appetite suppression (GLP-1 + GIP) plus increased calorie burning (glucagon) — the result is weight loss substantially greater than what any single-mechanism or dual-mechanism drug achieves.

Phase 2 results: the first signal

Phase 2 results, published in The New England Journal of Medicine in June 2023, evaluated retatrutide in 338 adults with obesity over 48 weeks. There was no diabetes in this population — these were people with obesity alone.

Results at 48 weeks:

At 24 weeks, the 12 mg group had already lost 17.5% of body weight — which is roughly what Wegovy produces over a full 68-week trial.

These Phase 2 numbers immediately set retatrutide apart from every other GLP-1-class drug studied to that point. The question was whether Phase 3 would confirm them.

Phase 3 results: the landmark numbers

Eli Lilly has been running the TRIUMPH Phase 3 programme since 2023. Results have started emerging.

TRIUMPH-4: Obesity with knee osteoarthritis (December 2025)

This Phase 3 trial enrolled adults with obesity and knee osteoarthritis — a population where weight loss would be expected to have dual benefits: metabolic and joint.

• Duration: 68 weeks
• Dose: 12 mg (top dose)
• Average weight loss: 71.2 lbs (32.3 kg)
• Percentage weight loss: approximately 32.3%
• Knee pain: 75.8% average reduction in WOMAC pain score at the 9 mg dose

The 71.2 lb average weight loss is the highest average weight loss ever recorded in any drug trial. For context:

Important caveat: These trials enrolled different populations, used different inclusion criteria, and ran at different times. The numbers cannot be directly compared as if it were a head-to-head trial. The TRIUMPH-4 osteoarthritis population may have different baseline characteristics that affect weight loss outcomes.

Still: the scale of the difference is striking, and it is consistent with what the Phase 2 data predicted.

TRIUMPH Type 2 Diabetes (March 2026)

Phase 3 results in the type 2 diabetes population were announced March 19, 2026. Retatrutide met its primary endpoint — significant reductions in HbA1c alongside meaningful weight loss in T2D patients. Full data has been submitted for publication.

Main obesity trial (pending)

The pivotal obesity trial — the one needed for an FDA obesity indication submission — has not yet reported results. This data is essential for the regulatory submission.

The osteoarthritis finding: beyond weight

The TRIUMPH-4 knee pain result deserves its own attention.

A 75.8% average reduction in WOMAC knee pain scores is not just impressive — it represents a potentially transformative benefit for the hundreds of millions of people worldwide who have both obesity and osteoarthritis.

The relationship between obesity and joint disease is well established: excess weight directly increases mechanical load on joints and drives inflammatory processes that accelerate cartilage degradation. Weight loss reduces both.

But the magnitude of pain reduction in TRIUMPH-4 — from a drug taken once weekly — suggests either that the weight loss effect on joints is larger than previously appreciated at this level of loss, or that retatrutide has anti-inflammatory effects beyond weight loss. Researchers are investigating both possibilities.

If retatrutide receives a specific indication for obesity with musculoskeletal complications, it would be the first weight loss drug approved with a joint pain claim — a meaningful addition to how physicians frame treatment decisions.

Liver disease: a likely additional benefit

Retatrutide's glucagon receptor component directly targets liver fat. Fatty liver disease (metabolic dysfunction-associated steatotic liver disease, MASLD) affects approximately 25% of the global population and is strongly linked to obesity and insulin resistance.

All GLP-1 drugs reduce liver fat somewhat — primarily through weight loss. Retatrutide's glucagon component adds a direct hepatic effect that may be additive. Early data suggests retatrutide may produce significant reductions in liver fat independent of the weight loss component alone.

Formal NAFLD/MASLD trials for retatrutide are underway. This indication could expand the drug's clinical reach substantially when the data matures.

Side effects

Phase 2 and Phase 3 data show a side effect profile consistent with the GLP-1 medication class:

Most common:

• Nausea (most common, especially during dose escalation)
• Diarrhoea
• Vomiting
• Constipation
• Decreased appetite

Pattern: GI side effects were dose-dependent — more common and more pronounced at the 12 mg dose than at lower doses — but generally mild to moderate in severity and decreased significantly over time as participants adjusted.

No new safety signals: Across Phase 2 and Phase 3 data to date, no unexpected or novel safety concerns have emerged. The safety profile appears consistent with the broader GLP-1 class.

Heart rate effects warrant watching. Glucagon receptor activation can increase resting heart rate. The clinical significance in the TRIUMPH programme has not raised a regulatory concern, but it will be a parameter the FDA examines closely.

When will retatrutide be available?

As of March 2026: not yet available outside of clinical trials.

The main obesity pivotal trial data is still pending. FDA submission requires that data, plus the full dossier from all TRIUMPH programme trials. The most optimistic scenario for a regulatory submission is late 2026, with approval possibly in 2027.

Do not fall for fraudulent products. Retatrutide is not commercially available anywhere. Any product claiming to be retatrutide — from compounding pharmacies, online sellers, or peptide supplement companies — is fraudulent and potentially dangerous.

If you want to access retatrutide legally today, the only path is clinical trial participation. Search clinicaltrials.gov for "retatrutide" to see if you meet eligibility criteria for any ongoing study.

How retatrutide fits in the pipeline context

The GLP-1 drug pipeline has moved extraordinarily fast. Placing retatrutide in context:

Retatrutide is the most powerful pharmacological weight loss agent in the pipeline by a considerable margin. When it reaches patients — most likely 2027 — it will likely become the first-choice option for patients with severe obesity who need maximum efficacy.

Final takeaway

Retatrutide is a once-weekly triple agonist (GLP-1 + GIP + glucagon) that has produced the highest average weight loss ever recorded in a clinical drug trial — 71.2 lbs over 68 weeks. Phase 3 results in type 2 diabetes are also strong.

It is not yet FDA approved, and approval is not expected before 2027. When it does reach patients, it will almost certainly represent the most powerful pharmacological weight loss option available.

For now, the best options for patients are the approved drugs — Wegovy, Zepbound, or Wegovy HD — while the retatrutide development programme concludes.

Related Articles

• New GLP-1 Drugs Pipeline 2026–2027: What's Coming
• CagriSema: Novo Nordisk's 22.7% Weight Loss Drug Explained
• Switching from Ozempic to Mounjaro: What to Know

Consult your healthcare provider before making any decisions about treatment changes based on pipeline data.

Sources

• Retatrutide drug information: drugs.com/history/retatrutide.html
• ClinicalTrials.gov: https://clinicaltrials.gov/
• NIDDK — prescription medicines for weight management: https://www.niddk.nih.gov/health-information/weight-management/prescription-medications-treat-overweight-obesity
• STEP 1 semaglutide trial — PubMed: https://pubmed.ncbi.nlm.nih.gov/33567185/